TODAY'S HEADLINES

FDA approves Harvoni for new uses

By Christine Blank
FDA recently approved Harvoni (ledipasvir/sofosbuvir) for expanded use in patients with genotype 4, 5 and 6 chronic hepatitis C virus (HCV) infection – as well as in hepatitis C patients co-infected with HIV. Read more

First-of-its kind myeloma drug approved

by Christine Blank
FDA has granted accelerated approval for daratumumab (Darzalex) injection for intravenous infusion for the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent. Read more

CONTINUING EDUCATION

November 2015
Recognition of drug-induced pulmonary disease and management of idiopathic pulmonary fibrosis

Session code: 15DT36-KXF58

This month's CE activity is part of the CPE series, "Medication Therapy Management for the Patient with Respiratory Disease." From April 2015 through December 2015, pharmacists can earn up to 18 hours of CPE credit with 9 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this activity is to review the common medications associated with pulmonary toxicity and to review how to recognize and treat idiopathic pulmonary fibrosis.

To read and print the article with TEST QUESTIONS, click here.

To proceed to the online exams and earn up to 2 CPE credits, click here to log in with the session code 15DT36-KXF58.
Copy the session code — 15DT36-KXF58  — before logging into the Online CE Center. When the page for the Online CE Center opens, paste the session code into the appropriate field, under your NABP ID.

EDITOR'S PICK

FDA approves Yondelis for LPS, LMS

by Christine Blank
FDA recently approved trabectedin (Yondelis) for the treatment of patients with unresectable or metastatic liposarcoma (LPS) or leiomyosarcoma (LMS) who received a prior anthracycline-containing regimen. Details

November 20, 2015

Related Articles

Harvoni could save US, Europe $3.2 billion

Cancer drug makers overcharge 600 times

Resources

Get the latest FormularyWatch updates on drug approvals, current studies, and other findings.

Click for the latest Clinical News